Interleukin-17 (IL-17) is an essential proinflammatory cytokine, which is mainly secreted by
the CD4+ helper T cells (Th17 cells) and subsets of innate lymphoid cells. IL-17A is …

Psoriatic arthritis (PsA), a heterogeneous chronic inflammatory immune-mediated disease
characterized by musculoskeletal inflammation (arthritis, enthesitis, spondylitis, and …

Objectives To update the Assessment of SpondyloArthritis international Society (ASAS)-
EULAR recommendations for the management of axial spondyloarthritis (axSpA). Methods …

Background Bimekizumab is a monoclonal IgG1 antibody that selectively inhibits interleukin
(IL)-17F and IL-17A. This study compared the efficacy and safety of bimekizumab with …

Background Bimekizumab is a monoclonal IgG1 antibody that selectively inhibits interleukin
(IL)-17A and IL-17F. We assessed the efficacy and safety of bimekizumab in patients with …

Background Upadacitinib is a Janus kinase inhibitor under evaluation for the treatment of
psoriatic arthritis (PsA). We evaluated upadacitinib in patients with PsA and prior inadequate …

Objectives Janus kinase inhibitors (JAKi) have been approved for use in various immune-
mediated inflammatory diseases. With five agents licensed, it was timely to summarise the …

Objectives MAXIMISE (Managing AXIal Manifestations in psorIatic arthritis with
SEcukinumab) trial was designed to evaluate the efficacy of secukinumab in the …

Objective To evaluate risankizumab, a biological therapy that inhibits interleukin 23, in
patients with active psoriatic arthritis (PsA) who have responded inadequately or are …

Psoriatic arthritis (PsA) is a heterogenous, chronic, inflammatory musculoskeletal disease
that can lead to peripheral and axial damage and loss of function. Axial involvement occurs …